Home
Vaccines
Recent developments in vaccine research have included many compounds reaching the market and several compounds are in late stages of clinical trials. It has been estimated that the vaccine market will grow to $10 billion by 2010.

SAE Media Group’s conference Vaccines aims to cover:
The recent developments in the vaccine market
The developments in therapeutic areas such as infectious diseases and cancer
New areas of research such as dendritic cells and immunotherapies: case studies of compounds and where these are leading
Manufacturing problems and strategies to overcome them

Hear contributions from experienced industry speakers:
· Dr Stephen Lockhart, Senior Director, Head, Bacterial Vaccine Clinical Research, Wyeth Vaccine Research
· Dr Derek O’Hagan, Senior Director, Vaccine Delivery, Chiron
· Dr Michael Watson Executive Director, Clinical Development, Europe, Aventis Pasteur
· Dr Anne-Marie Georges, Director, Regulatory Affairs, Legal & Information, GlaxoSAE Media GroupthKline Biologicals
· Dr Brian Ledwith, Director, Biologics Safety Assessment, Merck Research Laboratories
· Dr George Kemble, Senior Director, Research, MedImmune
· Dr David Urdal, President & Chief Scientific Officer, Dendreon
· Dr Arthur Krieg, Chief Scientific Officer, Coley Pharmaceutical

Key issues that will be addressed at the Conference:
· THE VACCINE MARKET: review the marketplace by assessing its drivers and challenges
· REGISTERING NEW VACCINES: hear about obstacles and challenges you may encounter
· THE CLINICAL TRIALS DIRECTIVE: assess what effect it will have on the vaccines market and how to streamline regulations in the US & Europe
· NOVEL VACCINES APPROACHES: get an update on vaccines developments for Cancer, SARS, Influenza, Hepatitis B and C
· MANUFACTURING VACCINES: understand problems & challenges when producing vaccines
· SAFETY & EFFICACY: how big and how long do studies need to be? Will the need for ‘gold-standard’ end-points inhibit new vaccine development?

“Very good speakers, collegial environment, well run Conference”
Dr Jennifer Cygan, Genencor, delegate at SAE Media Group’s Conference Vaccines 2002

Conference agenda

clock

8:30

Registration and Coffee

clock

8:50

Chairman's Opening Remarks

Piers Whitehead

Piers Whitehead, Vice President Corporate & Business Development, VaxGen

clock

9:00

Biodefence vaccines and the public

Dr Tim Brooks

Dr Tim Brooks, Director of Public Health Affairs , Health Protection Agency, Centre for Applied Microbiology and Research (CAMR)

  • What are the advantages and disadvantages of mass vaccination campaigns?
  • How do you educate the public on the risks and benefits of any vaccination strategy?
  • Should we offer pre-exposure vaccination against BT agents?
  • When should post-exposure vaccination be used? For whom?
  • clock

    9:40

    Biodefence and working with the Government

    Kevin Price

    Kevin Price, Commercial Director, Avecia

  • Review history of bioweapons
  • Review highest risk pathogens
  • BioShield initiative
  • Proposal and contracting process
  • Awards made to date
  • clock

    10:20

    Morning Coffee

    clock

    10:35

    The Business of Bio-Defence

    Piers Whitehead

    Piers Whitehead, Vice President Corporate & Business Development, VaxGen

  • Key issues regarding the availability of smallpox and anthrax vaccines
  • The purpose of developing and commercialising vaccines against bioterrorism
  • Preclinical and clinical results of rPA102
  • The scale up and validation of the vaccine manufacturing process
  • clock

    11:15

    The UK recombinant plague vaccine: progress on meeting the unique regulatory requirements to licence a biodefence vaccine

    Dr Phil Packer

    Dr Phil Packer, Project Manager, Defence Science & Technology Laboratory (DSTL)

  • Preclinical pharmacokinetics and toxicology data
  • Phase I clinical trial – evidence of the safety of the vaccine in man
  • Evidence of efficacy in animal models
  • Strategy to meet regulatory approval
  • Surrogate markers of protection
  • clock

    11:55

    Biodefence vaccines – the prime systems contract approach

    Terry Irgens, Ms, CAAMA

    Terry Irgens, Ms, CAAMA, President, DynPort Vaccine

  • About the prime systems model
  • Case study: Joint Vaccine Acquisition Program
  • Current status of biodefence vaccines and therapeutics
  • Advancements in biodefence vaccine development
  • clock

    12:35

    Discussion and questions – review of the session

    clock

    13:00

    Close of Executive Briefing followed by Lunch

    clock

    8:30

    Registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Philip Minor

    Dr Philip Minor, Head, Division Virology, National Institue for BIological Standards and Control

    clock

    9:10

    KEYNOTE ADDRESS

    Dr John Savopoulos

    Dr John Savopoulos, Head, Infectious Diseases (ID) Business Unit, Datamonitor Healthcare (Europe)

  • Who is doing what?
  • Which are the most promising approaches?
  • The challenges that have been overcome since 2003
  • Which are the emerging trends in the vaccine market?
  • Where is the market heading?
  • Review the FDA process and international issues regarding the development of new vaccines and related delivery systems
  • clock

    9:40

    CLINICAL DEVELOPMENT CHALLENGES

    Dr Stephen Lockhart

    Dr Stephen Lockhart, Senior Director, Head, Bacterial Vaccine Clinical Research, Wyeth Vaccine Research

  • Meeting clinical trial regulatory needs
  • Dealing with multiple paediatric vaccines recommendations
  • Defining non-inferiority in comparisons of study vaccines and concomitant vaccines
  • Safety: how big and how long do studies need to be?
  • Efficacy: will the need for ‘gold-standard’ end-points inhibit new vaccine development?
  • clock

    10:20

    THE CLINICAL TRIALS DIRECTIVE AND ITS APPLICATION TO VACCINES

    Dr Anne-Marie Georges

    Dr Anne-Marie Georges, Director, Regulatory Affairs, Legal and Information, GlaxoSmithkline Biologicals

  • General issues with the Directive in comparison to the US
  • Ethics Committee approval
  • Regulatory dossier requirements
  • Approval procedure by regulatory authorities
  • Delays to clinical research with vaccines
  • Generics to biologicals: new rule in the EU
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    CASE STUDY

    Dr Derek O’Hagan

    Dr Derek O’Hagan, Senior Director, Vaccine Delivery, Chiron

  • Safety and efficacy of a wide range of vaccines, including influenza vaccine in the elderly (Fluad)
  • Potential for use against flu strains
  • Safety in young patients
  • Development of new generation of vaccine
  • clock

    12:00

    MOLECULAR CHARACTERISATION AND PRODUCTION OF COLD-ADAPTED, LIVE ATTENUATED INFLUENZA VACCINE, FLUMIST

    Dr George Kemble

    Dr George Kemble, Senior Director, Research, MedImmune

  • Molecular genetics of the temperature sensitive and attenuation phenotypes
  • Use of plasmid technologies to generate vaccine strains
  • Mechanisms of immune response to vaccine strains
  • clock

    12:40

    Networking Lunch

    clock

    14:00

    CASE STUDY: IMMUNOTHERAPIES

    Dr Steve Chatfield

    Dr Steve Chatfield, Chief Scientific Officer, Microscience

  • Challenges with the development of live vaccines
  • Choice of antigens
  • Optimisation of expression of antigens
  • Preclinical/clinical data
  • clock

    14:40

    TOWARDS AN HCV VACCINE

    Prof Willy Spaan

    Prof Willy Spaan, Scientific Co-ordinator, European HCV Consortium

  • Hepatitis C virus
  • Correlates of protection
  • Vaccines
  • Animal studies
  • EU-FP5
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    CHIMIGEN™ VACCINES: A NOVEL CLASS OF THERAPEUTIC VACCINES FOR THE TREATMENT OF CHRONIC VIRAL INFECTIONS

    Dr Antoine Noujaim

    Dr Antoine Noujaim, President & Chief Executive Officer, ViRexx Research

  • ChimigenTM vaccines are recombinant fusion proteins with attributes of both a viral antigen and a monoclonal antibody
  • Unique chimeric design facilitates the formation of antibody like structure and appropriate antigen presentation
  • Adaptable platform, can be used to develop vaccines against any infectious agent
  • Targets the proper compartments of the antigen presenting cells to elicit cellular as well as humoral immune response
  • Generates broad immune response, both cellular (class I presentation) and humoral (class II presentation) to attack the infectious agent and break tolerance to the antigens
  • Can be used as either a therapeutic or a prophylactic vaccine
    Several therapeutic vaccine candidates at preclinical stage for the treatment of chronic Hepatitis B and C infections
  • clock

    16:20

    STRATEGIC DEVELOPMENT AND MANUFACTURING

    Dr Ronald Ellis

    Dr Ronald Ellis, Senior Vice President, Research & Development & General Manager, Shire Biologics

  • Defining strategic issues early in a development program
  • Types of vaccine technologies
  • Development and clinical needs for these technologies
  • Long-term planning for manufacturing
  • Practical examples
  • clock

    17:00

    Chairman's Closing Remarks and Close of Day One

    clock

    8:30

    Re-registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Prof Willy Spaan

    Prof Willy Spaan, Scientific Co-ordinator, European HCV Consortium

    clock

    9:10

    CANCER VACCINES AND OTHER RETRO FASHIONS IN BIOTECH

    Mark Leuchtenberger

    Mark Leuchtenberger, President & Chief Executive Officer, Therion Biologics

  • The therapeutic cancer vaccine field has seen several clinical trials failures in recent years
  • Therapeutic vaccine development may mirror the bumpy road to commercialisation taken by monoclonal antibody technology, which endured its own high-profile failures before becoming fashionable again as biotech's leading technology
  • Review how Therion Biologics is driving to proof-of-concept phase II trials
  • clock

    9:40

    IMMUNOTHERAPY FOR CANCER

    Dr David Urdal

    Dr David Urdal, President & Chief Scientific Officer, Dendreon

  • Results from a double-blind, placebo-controlled clinical study of a therapeutic prostate cancer vaccine
  • Strategies for optimisation of cancer vaccines
  • Induction of cancer-specific immunity in humans
  • clock

    10:20

    ANTIBODIES AS VACCINES

    Dr Antoine Noujaim

    Dr Antoine Noujaim, President & Chief Executive Officer, ViRexx Research

  • Monoclonal antibodies in cancer treatment
  • Mechanisms of immune activation by low-dose xenotypic monoclonal antibodies
  • Critical components to target activating receptors on dendritic cells
  • Broad technology application for cancer and infectious diseases
  • Documented proof of principle in ovarian cancer
  • Clinical challenges for immune therapeutic approaches to cancer
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    CANCER VACCINE CASE STUDY: TROVAX

    Dr Miles Carroll

    Dr Miles Carroll, Vice President, Immunotherapy, Oxford BioMedica

  • TroVax: highly attenuated poxvirus expressing the novel TAA 5T4
  • Pre-clinical package
  • Results from a colorectal cancer phase I/II clinical trial
  • Future clinical development
  • clock

    12:00

    ENHANCING VACCINATION BY ADDITION OF ADJUVANTS THAT ACTIVATE DENDRITIC CELLS IN VIVO THROUGH TLR9

    Grayson B. Lipford

    Grayson B. Lipford, Director, Basic Research, Coley Pharmaceutical

  • The mechanisms through which TLR9 activation with CpG oligos trigger innate and adaptive immunity
  • The ways in which activating TLR9 differs from other vaccine adjuvants
  • The preclinical data with CpG in animal vaccine models
  • Clinical data with CpG 7909 in human vaccine trials, showing accelerated seroconversion and reduced non-responders
  • clock

    12:40

    Networking Lunch

    clock

    14:00

    ADVANCES IN TECHNOLOGIES FOR THE PURIFICATION AND MANUFACTURING OF VACCINES

    Sandra Merino

    Sandra Merino, Business Development Manager, Alfa Wassermann

  • Historical evolution of vaccine development and manufacturing methodologies
  • Overview and examples of current methods used in vaccine purification
  • Approaches to enable process scalability – from development through to manufacturing
  • clock

    14:40

    STRATEGIC AND PRACTICAL CONSIDERATIONS TO THE DEVELOPMENT OF COMBINATION VACCINES

    Dr Michael Watson

    Dr Michael Watson , Executive Director, Clinical Development, Europe, Aventis Pasteur MSD

  • Efficacy vs immunogencity
  • Safety
  • Concomitant administration; antigens vs products
  • Post licensure commitments
  • Future combinations
  • clock

    15:20

    NON-CLINICAL SAFETY TESTING OF NOVEL VACCINE AND ADJUVANT TECHNOLOGIES

    Dr Frank Brennan

    Dr Frank Brennan, Project Director, Biopharmaceuticals, Huntingdon Life Sciences

  • General considerations in demonstrating safety, pharmacology and efficacy of vaccines and adjuvants
  • Design of in silico, in vitro and in vivo studies to support safety
  • Design of studies to assess systemic and local toxicity, immunogenicity and immunotoxicity, reproductive toxicity, safety pharmacology and genotoxicity
  • Safety considerations for novel mucosal and parenteral adjuvants
  • Safety testing of novel vaccines: recombinant protein vaccines, live attenuated vaccines and vectors, DNA and gene therapy based vaccines, whole mammalian cell vaccines
  • clock

    16:00

    Chairman's Closing Remarks and Close of Conference

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.